Shots:
- The two companies will co-develop and conduct clinical trials for senaparib across multiple cancer indications in China. Junshi to invest $43.4M in cash, representing 50% of the JV while Impact will supply senaparib in Mainland China, Hong Kong, and Macau representing the other 50%
- The JV will focus on the research, development & commercialization of the therapy in the territory. Both the companies will leverage the team’s strength to expedite the clinical development of IMP4297 and explore additional indications with the therapy
- Senaparib is a PARP inhibitor, currently being evaluated in multiple P-I & II studies in multiple settings. The drug has been tested in 100+ patients with advanced solid tumors in multiple clinical trials in China and Australia
Click here to read full press release/ article | Ref: PRNewswire | Image: Modern Medicines
